Τίτλος:
MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study
of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable
stage IIIB-IVM1c melanoma (MEL)
Συγγραφείς:
Ribas, A.
Chesney, J.
Long, G. V.
Kirkwood, J. M. and
Dummer, R.
Puzanov, I.
Hoeller, C.
Gajewski, T. F. and
Gutzmer, R.
Rutkowski, P.
Demidov, L.
Arenberger, P. and
Shin, S. J.
Ferrucci, P. F.
Diede, S. J.
Anderson, J. R. and
Treichel, S.
Chan, E.
Hodi, F. S.
Gogas, H. J.
